Posts tagged DNDi

Photo: Patients in the waiting area at Koutiala Hospital in Mali. Mali 2012 © Venetia Dearden
Conference Briefing Paper: Medical Innovations for Neglected PatientsThere are three fundamental problems with medical innovation today. 
First, global public health needs are not in the driving seat. Regardless of how great the needs may be, where commercial potential is weak, there is little “pull” to develop new technologies. The innovation cycle is broken, with few or no incentives for the development of effective, safe, quality, suitable and affordable health technologies—leading to needless suffering and death. 
Second, as a result, developing countries must often “make do” with innovation that primarily caters to conditions in developed countries. Medical tools are too often developed first for developed countries and only rolled out in resource limited settings in a second stage. 
Third, even when there is enough of a profit incentive to drive innovation—for example when diseases affect both developed and developing countries alike—the resulting products are too often priced out of reach. 
Medical innovation must aim to change practice, for the benefit of patients. But ideas, knowledge and inventions can only benefit patients who have access to the fruits of innovation. What is needed, therefore, is not just innovation—but both innovation and access.
Download the full report here.

Photo: Patients in the waiting area at Koutiala Hospital in Mali. Mali 2012 © Venetia Dearden

Conference Briefing Paper: Medical Innovations for Neglected Patients
There are three fundamental problems with medical innovation today. 

First, global public health needs are not in the driving seat. Regardless of how great the needs may be, where commercial potential is weak, there is little “pull” to develop new technologies. The innovation cycle is broken, with few or no incentives for the development of effective, safe, quality, suitable and affordable health technologies—leading to needless suffering and death. 

Second, as a result, developing countries must often “make do” with innovation that primarily caters to conditions in developed countries. Medical tools are too often developed first for developed countries and only rolled out in resource limited settings in a second stage. 

Third, even when there is enough of a profit incentive to drive innovation—for example when diseases affect both developed and developing countries alike—the resulting products are too often priced out of reach. 

Medical innovation must aim to change practice, for the benefit of patients. But ideas, knowledge and inventions can only benefit patients who have access to the fruits of innovation. What is needed, therefore, is not just innovation—but both innovation and access.

Download the full report here.

Photo: South Sudan 2012 © John Stanmeyer/VII
International Medical Conference to Assess Progress and Shortcomings of Global Health Revolution for Neglected Patients
Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations will bring together top minds in global health. The goal will be to examine the progress and shortcomings of a decade’s worth of international initiatives aimed at addressing urgent health needs of the poorest populations in the world.
Register for the online webcast

Photo: South Sudan 2012 © John Stanmeyer/VII

International Medical Conference to Assess Progress and Shortcomings of Global Health Revolution for Neglected Patients

Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations will bring together top minds in global health. The goal will be to examine the progress and shortcomings of a decade’s worth of international initiatives aimed at addressing urgent health needs of the poorest populations in the world.

Register for the online webcast

This week, we’re excited to be sending you updates from the 2012 International AIDS Conference in Washington DC. 

We’re kicking the conference off today with a satellite session on global innovation. This and other events will be webcast live at http://aids2012.msf.org/.

This week, we’re excited to be sending you updates from the 2012 International AIDS Conference in Washington DC.

We’re kicking the conference off today with a satellite session on global innovation. This and other events will be webcast live at http://aids2012.msf.org/.

Fighting Neglect: Sleeping Sickness

Sleeping Sickness is a fatal and much neglected disease that plagues parts of Africa.

Learn more about sleeping sickness and other neglected diseases.

Fighting Neglect: Kala azar

Kala Azar is a neglected tropical disease responsible for 50,000 deaths every year.Kala azar is a disease that, if left untreated, is 100 percent fatal. To break the vicious cycle that leaves tropical diseases like Kala azar neglected, existing programs that diagnose and treat patients need to be expanded and medical research to develop simpler, more effective tools needs to be supported.

Learn more about Kala Azar and other neglected diseases.

Fighting Neglect: Chagas:

Chagas is a parasitic disease found on the American continent, where it affects an estimated 8 to 10 million people and claims up to 12,500 lives every year.

Learn more about Chagas and other neglected diseases.

170 plays

Podcast - MSF Frontline Reports:
Children With HIV Need More Treatment Options; DNDi Aims To Help Fill The Void

Without proper treatment, half of the 370,000 children newly infected with HIV last year will die before they reach their second birthday. But very few medicines are designed and adapted specifically for children, and are affordable and practical to use in the places where they live. The Drugs for Neglected Diseases initiative (DNDi) recently announced a new project to help develop appropriate HIV drugs for children. Visit DNDi at www.dndina.org.

2007A New Treatment for Malaria

The Drugs for Neglected Diseases Initiative and the pharmaceutical company sanofi-aventis launch ASAQ, an inexpensive and easy-to-use combination pill. ASAQ is not patented, allowing for others to produce it at lower cost.

Learn more about MSF’s history at our website.

Photo: France 2007 © DNDi

2007
A New Treatment for Malaria

The Drugs for Neglected Diseases Initiative and the pharmaceutical company sanofi-aventis launch ASAQ, an inexpensive and easy-to-use combination pill. ASAQ is not patented, allowing for others to produce it at lower cost.

Learn more about MSF’s history at our website.

Photo: France 2007 © DNDi